Selling Celera Dx Stake to Celera Genomics, ABI Bets That Its Tools Will See FDA OK for Dx Apps | GenomeWeb

Applied Biosystems is getting into the platform side of the molecular diagnostics game after selling its half of the Celera Diagnostics joint venture to the firm's other owner, Applera sister company Celera Genomics, and setting its sights on eventually clearing some of its platforms with the US Food and Drug Administration for molecular diagnostics applications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.